Innoviva Inc
INVA
Company Profile
Business description
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Contact
1350 Old Bayshore Highway
Suite 400
BurlingameCA94010
USAT: +1 650 238-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
159
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,810.60 | 89.10 | -1.00% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,024.48 | 269.55 | -1.07% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 52,780.13 | 959.55 | -1.79% |
| NZX 50 Index | 12,865.18 | 39.31 | 0.31% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,612.20 | 72.80 | -0.84% |
| SSE Composite Index | 3,933.16 | 15.39 | -0.39% |